Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Real Time Quote from BATS)

$6.76 USD

6.76
1,061,636

+0.04 (0.60%)

Updated Jul 22, 2024 09:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.

Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.

AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?

by Zacks Equity Research

Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.

Ocugen (OCGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Ocugen (OCGN) is likely to provide updates related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports second-quarter 2021 results.

What's in Store for Senseonics Holdings' (SENS) Q2 Earnings?

by Zacks Equity Research

Senseonics Holdings' (SENS) second-quarter results are likely to gain from higher sales outside the United States.

DENTSPLY SIRONA (XRAY) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.

BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment is expected to have driven up Q3 sales.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?

by Zacks Equity Research

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.

Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

by Ekta Bagri

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

Abiomed (ABMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q1 sales.

Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Incyte (INCY) to Post Q2 Earnings: Will Jakafi Sales Disappoint?

by Zacks Equity Research

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports second-quarter 2021 results.

Gilead (GILD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports second-quarter 2021 results.

Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.

Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

by Zacks Equity Research

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

Minerva (NERV) Soars on Promising Schizophrenia Study Data

by Zacks Equity Research

Minerva (NERV) is developing its lead pipeline candidate, roluperidone, in patients with negative symptoms of schizophrenia. Positive data from an extension of previously completed late-stage study boosts investors' sentiment.

Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.

Moving Average Crossover Alert: Ironwood Pharmaceuticals (IRWD)

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.